FDA Accepts Biohaven’s Resubmitted Application for Troriluzole in Spinocerebellar Ataxia
Biohaven’s Vyglxia resubmission for SCA accepted for review by the FDA. Target action date is the first quarter of 2027.
Biohaven’s Vyglxia resubmission for SCA accepted for review by the FDA. Target action date is the first quarter of 2027.
The FDA has paused new patient enrollment in Biohaven’s BHV-7000 epilepsy studies after rodent findings. Dosing continues for current participants.
SK Biopharm gains exclusive worldwide rights to Biohaven’s opakalim and Kv7 platform in a deal worth up to $795M, with a possible 2029 U.S. launch.
Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.
Biohaven shares rose after strong early results from 2 drugs that quickly lower harmful antibodies in autoimmune diseases.
Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.